Compare ANEB & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANEB | VNRX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 38.2M |
| IPO Year | 2021 | N/A |
| Metric | ANEB | VNRX |
|---|---|---|
| Price | $1.09 | $0.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 138.8K | ★ 2.7M |
| Earning Date | 02-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.98 |
| Revenue Next Year | N/A | $420.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $0.90 | $0.22 |
| 52 Week High | $3.42 | $0.94 |
| Indicator | ANEB | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.03 | 47.78 |
| Support Level | $1.02 | $0.31 |
| Resistance Level | $1.14 | $0.39 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 48.34 | 41.70 |
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.